Effects of Sulindac Sulfide on Proliferation and Apoptosis of Human Breast Cancer Cell

Overview

Journal Oncol Lett

Specialty Oncology

Date 2018 Jun 1

PMID 29849803

Citations 4

Authors

He-Huan Sui

Yun-Jiang Zhou

Hu Wang

Li Li

Min Cao

Jia-Jun Huang

Affiliations

Soon will be listed here.

Abstract

The present study aimed to observe the effects of sulindac sulfide on the proliferation and apoptosis of human breast cancer cells MCF-7, and to explore the potential underlying molecular mechanism. The inhibitory ratio was detected using a cell counting kit-8 assay. The changes in cell cycle distribution were assessed using flow cytometry (FCM). Furthermore, the changes in cell apoptosis rates were detected by Hoechst 33258 staining and FCM coupled with Annexin V-FITC/propidium iodide (PI) staining. In addition, the protein expression was detected using western blotting. Sulindac sulfide was able to inhibit the proliferation of breast cancer in a dose- and time-dependent manner. In addition, sulindac sulfide altered the cell cycle of breast cancer cells. The results of Hoechst 33258 staining and FCM coupled with Annexin V-FITC/PI staining demonstrated that sulindac sulfide could significantly induce the apoptosis of MCF-7 cells in a dose-dependent, and time-dependent manner. The western blot analysis demonstrated the protein expression of Bcl-2 was downregulated, and Bax and cleaved caspase-3 were upregulated. The results of the present study suggest that sulindac sulfide can inhibit the proliferation and induce the apoptosis of MCF-7 cells.

Citing Articles

Sulindac exhibits anti-proliferative and anti-invasive effects in uterine serous carcinoma cells.

Chen S, Kong W, Shen X, Deng B, Haag J, Sinha N J Cancer Res Clin Oncol. 2024; 150(8):402.

PMID: 39198302 PMC: 11358172. DOI: 10.1007/s00432-024-05926-9.

Sulindac sulfide as a non-immune suppressive γ-secretase modulator to target triple-negative breast cancer.

Hossain F, Ucar D, Monticone G, Ran Y, Majumder S, Larter K Front Immunol. 2023; 14:1244159.

PMID: 37901240 PMC: 10612326. DOI: 10.3389/fimmu.2023.1244159.

Novel Non-Cyclooxygenase Inhibitory Derivative of Sulindac Inhibits Breast Cancer Cell Growth In Vitro and Reduces Mammary Tumorigenesis in Rats.

Tinsley H, Mathew B, Chen X, Maxuitenko Y, Li N, Lowe W Cancers (Basel). 2023; 15(3).

PMID: 36765604 PMC: 9913705. DOI: 10.3390/cancers15030646.

Unboxing the molecular modalities of mutagens in cancer.

Kumari S, Sharma S, Advani D, Khosla A, Kumar P, Ambasta R Environ Sci Pollut Res Int. 2021; 29(41):62111-62159.

PMID: 34611806 PMC: 8492102. DOI: 10.1007/s11356-021-16726-w.

References

Zhang Y, Ouyang D, Xu L, Ji Y, Zha Q, Cai J . Cucurbitacin B induces rapid depletion of the G-actin pool through reactive oxygen species-dependent actin aggregation in melanoma cells. Acta Biochim Biophys Sin (Shanghai). 2011; 43(7):556-67. DOI: 10.1093/abbs/gmr042. View

Mahmoud N, Boolbol S, Dannenberg A, Mestre J, Bilinski R, Martucci C . The sulfide metabolite of sulindac prevents tumors and restores enterocyte apoptosis in a murine model of familial adenomatous polyposis. Carcinogenesis. 1998; 19(1):87-91. DOI: 10.1093/carcin/19.1.87. View

Chen Q, Ouyang D, Geng M, Xu L, Zhang Y, Wang F . Valproic acid exhibits biphasic effects on apoptotic cell death of activated lymphocytes through differential modulation of multiple signaling pathways. J Immunotoxicol. 2011; 8(3):210-8. DOI: 10.3109/1547691X.2011.568979. View

Levy D, Moser A, Dove W, Hamilton S, Vogelstein B, Kinzler K . Sulindac suppresses tumorigenesis in the Min mouse. Carcinogenesis. 1996; 17(8):1757-60. DOI: 10.1093/carcin/17.8.1757. View

Katoumas K, Nikitakis N, Perrea D, Dontas I, Sklavounou A . In Vivo Antineoplastic Effects of the NSAID Sulindac in an Oral Carcinogenesis Model. Cancer Prev Res (Phila). 2015; 8(7):642-9. DOI: 10.1158/1940-6207.CAPR-14-0447. View

Piazza G, Alberts D, Hixson L, Paranka N, Li H, Finn T . Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res. 1997; 57(14):2909-15. View

Li H, Yang A, Chung Y, Zhang W, Liao J, Yang G . Sulindac inhibits pancreatic carcinogenesis in LSL-KrasG12D-LSL-Trp53R172H-Pdx-1-Cre mice via suppressing aldo-keto reductase family 1B10 (AKR1B10). Carcinogenesis. 2013; 34(9):2090-8. PMC: 3765049. DOI: 10.1093/carcin/bgt170. View

Fu J, Xu X, Kang L, Zhou L, Wang S, Lu J . miR-30a suppresses breast cancer cell proliferation and migration by targeting Eya2. Biochem Biophys Res Commun. 2014; 445(2):314-9. DOI: 10.1016/j.bbrc.2014.01.174. View

Corbex M, Bouzbid S, Boffetta P . Features of breast cancer in developing countries, examples from North-Africa. Eur J Cancer. 2014; 50(10):1808-1818. DOI: 10.1016/j.ejca.2014.03.016. View

10.

Suk Lee Y, Choi D, Kim N, Yang S, Jung E, Hong M . CXCR2 inhibition enhances sulindac-mediated suppression of colon cancer development. Int J Cancer. 2013; 135(1):232-7. PMC: 4166491. DOI: 10.1002/ijc.28668. View

11.

Sinicrope F, Penington R . Sulindac sulfide-induced apoptosis is enhanced by a small-molecule Bcl-2 inhibitor and by TRAIL in human colon cancer cells overexpressing Bcl-2. Mol Cancer Ther. 2005; 4(10):1475-83. DOI: 10.1158/1535-7163.MCT-05-0137. View

12.

Verma R, Brahmankar M, Kushwah L, Suresh B . Evaluating the inhibitory potential of sulindac against the bleomycin-induced pulmonary fibrosis in wistar rats. Environ Toxicol Pharmacol. 2013; 36(3):769-78. DOI: 10.1016/j.etap.2013.07.011. View

13.

Fink S, Dawson D, Zhang Y, Kresak A, Lawrence E, Yang P . Sulindac reversal of 15-PGDH-mediated resistance to colon tumor chemoprevention with NSAIDs. Carcinogenesis. 2014; 36(2):291-8. PMC: 4322189. DOI: 10.1093/carcin/bgu241. View

14.

Diller M, Schuler S, Buchholz S, Lattrich C, Treeck O, Ortmann O . Effects of estriol on growth, gene expression and estrogen response element activation in human breast cancer cell lines. Maturitas. 2014; 77(4):336-43. DOI: 10.1016/j.maturitas.2014.01.004. View

15.

Giardiello F, Hamilton S, KRUSH A, Piantadosi S, Hylind L, Celano P . Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med. 1993; 328(18):1313-6. DOI: 10.1056/NEJM199305063281805. View

16.

Smalley W, Ray W, DAUGHERTY J, Griffin M . Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer: a population-based study. Arch Intern Med. 1999; 159(2):161-6. DOI: 10.1001/archinte.159.2.161. View

17.

Span P, Pollakis G, Paxton W, Sweep F, Foekens J, Martens J . Improved metastasis-free survival in nonadjuvantly treated postmenopausal breast cancer patients with chemokine receptor 5 del32 frameshift mutations. Int J Cancer. 2014; 136(1):91-7. DOI: 10.1002/ijc.28962. View

18.

Kim Y, Seol C, Jung J, Oh S, Hwang K, Kim H . Synergistic Effect of Sulindac and Simvastatin on Apoptosis in Lung Cancer A549 Cells through AKT-Dependent Downregulation of Survivin. Cancer Res Treat. 2014; 47(1):90-100. PMC: 4296852. DOI: 10.4143/crt.2013.194. View

19.

Liggett J, Min K, Smolensky D, Baek S . A novel COX-independent mechanism of sulindac sulfide involves cleavage of epithelial cell adhesion molecule protein. Exp Cell Res. 2014; 326(1):1-9. DOI: 10.1016/j.yexcr.2014.05.009. View

20.

Thompson H, Jiang C, Lu J, Mehta R, Piazza G, Paranka N . Sulfone metabolite of sulindac inhibits mammary carcinogenesis. Cancer Res. 1997; 57(2):267-71. View